CRISPR Therapeutics (CRSP)
(Real Time Quote from BATS)
$53.96 USD
-1.71 (-3.06%)
Updated Feb 8, 2023 11:13 AM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
CRSP 53.96 -1.71(-3.06%)
Will CRSP be a Portfolio Killer in February?
Zacks Investment Research is releasing its prediction for CRSP based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRSP
Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Markets: What You Should Know
CRSP: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?
Strength Seen in CRISPR Therapeutics AG (CRSP): Can Its 7.2% Jump Turn into More Strength?
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
Other News for CRSP
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
When Small Cap Biotechs Lose Momentum: Are You An Investor Or A Trader?
3 CRISPR Stocks to Buy Now Or You`ll Be Kicking Yourself Later
Michael Burry vs. Jim Cramer: Is It Time to Buy or Sell Stocks Now?
7 CRISPR Stocks With the Best Long-Term Potential��